Company / Net Income
Dianthus Therapeutics, Inc. /DE/ Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$162.3M
FY2025
5-year range
-$162.3M / -$28.5M
FY2021-FY2025
Trend
-272.7%
vs FY2024
Sector context
#139 of 216
Health Care
What the data says
Net Income changed -273% YoY in FY2025, a notable deviation from the 9-year average annual change of -70%.
Based on SEC 10-K filings.
-$162M in FY2025.
Declined from -$44M to -$162M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#139 of 216 in Health CareTop 64% of 216This company -$162.3M Sector average $454.1M
▼
-135.7% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 272.7% year-over-year.
- Ranks #139 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$162.3M | -272.7% |
| FY2024 | -$43.6M | +0.0% |
| FY2023 | -$43.6M | -53.0% |
| FY2022 | -$28.5M | +60.0% |
| FY2021 | -$71.1M | +5.1% |
| FY2020 | -$74.9M | +2.4% |
| FY2019 | -$76.8M | -33.5% |
| FY2018 | -$57.5M | -62.1% |
| FY2017 | -$35.5M | -276.3% |
| FY2016 | -$9.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026